Red Light Therapy When You're Sick: What's Proven—and What Isn't

Updated on August 18, 2026 | Estimated reading time: 14 minutes

Red light therapy is sometimes discussed during flu season because photobiomodulation (PBM) can influence cellular signaling in laboratory and preclinical studies. That biological interest should not be mistaken for proof that red or near-infrared light prevents influenza, reduces viral replication, relieves flu symptoms, or shortens recovery in people.

The evidence reviewed for this article did not identify a randomized controlled trial of PBM as a treatment for human influenza. There is also no established consumer protocol for influenza specifying a validated wavelength, irradiance, radiant exposure, treatment location, schedule, or device format.

This article therefore separates four different questions: what influenza does in the respiratory tract, what PBM may do at the cellular level, what human clinical evidence is actually available, and what safety and regulatory documents can—and cannot—tell you.

How influenza affects the respiratory tract

Conceptual influenza infection across the respiratory epithelium

Influenza is an acute respiratory infection caused by influenza viruses. The viruses can infect epithelial cells in the nose, throat, and lungs. Symptoms may include fever, cough, sore throat, headache, body aches, fatigue, and a runny or stuffy nose, although presentation varies by age, immune status, underlying conditions, and the circulating strain.

Both viral activity and the host response matter. Viral replication can injure infected epithelial cells, while immune signaling helps control the infection and also contributes to fever, fatigue, inflammation, and other symptoms. In severe disease, an excessive or poorly regulated inflammatory response may add to tissue injury. However, inflammation is also part of antiviral defense, so reducing an inflammatory marker in a laboratory model does not automatically improve infection outcomes.

This distinction is essential when evaluating PBM. A biological mechanism that changes cytokine signaling may be scientifically interesting without being clinically beneficial during influenza.

From early phototherapy to modern photobiomodulation

Historical timeline distinguishing different light-based medical approaches

The medical use of light includes several technologies that should not be treated as interchangeable. Niels Finsen received the 1903 Nobel Prize for his work using concentrated light to treat lupus vulgaris, a form of skin tuberculosis. That work involved different spectra, delivery methods, and biological objectives from modern red and near-infrared PBM.

In the 1960s, Endre Mester investigated low-power laser exposure. Early experiments included observations of hair growth in mice, followed by later animal work on wound healing. These studies helped establish the idea that low-intensity light could influence biology without cutting or ablating tissue.

LED systems later made it easier to deliver broader fields of red or near-infrared light. Research expanded into areas such as wound care, pain, inflammation, oral mucositis, exercise recovery, and other condition-specific applications. None of this historical development establishes effectiveness for influenza. Each condition, anatomical target, device, and dose requires its own evidence.

Proposed PBM mechanisms—and their limits

Evidence-aware photobiomodulation mechanism diagram

One proposed PBM pathway involves cytochrome c oxidase, an enzyme in the mitochondrial electron-transport chain. Other proposed pathways involve nitric oxide, calcium signaling, light-sensitive ion channels, and additional photoacceptors. Depending on the experimental system and exposure parameters, downstream signaling may include transient changes in ATP, reactive oxygen species, nitric oxide, calcium, transcription factors, and gene expression.

These responses are not uniform. They can vary with:

• Wavelength and spectral bandwidth
• Irradiance and radiant exposure
• Continuous or pulsed delivery
• Exposure area and geometry
• Cell and tissue type
• Baseline metabolic and inflammatory state
• Temperature and other experimental conditions

PBM is often described as having a biphasic dose response: increasing exposure does not necessarily increase benefit, and different outcomes may appear at different doses. This principle reinforces the need for condition- and device-specific clinical protocols. It does not provide a way to calculate a flu treatment from a panel specification or an in-vitro experiment.

General PBM reviews report changes in inflammatory markers under some experimental conditions. Those findings do not demonstrate that PBM produces a safer, more efficient, or more precise immune response during human influenza. They also do not establish an antiviral effect.

Why optical access does not establish clinical benefit

An intranasal emitter can place light close to the nasal mucosa, reducing the need for photons to pass through external skin and subcutaneous tissue. Even at close range, however, light is reflected, scattered, and absorbed. The dose reaching particular cells depends on the device geometry, spectrum, beam profile, contact conditions, tissue properties, and exposure time.

Fixed statements such as "red light penetrates exactly 1–3 mm" should not be treated as universal measurements. Penetration depth is defined differently across studies and changes with the tissue and optical setup. A skin review cannot by itself establish the dose delivered to human nasal mucosa.

Most importantly, anatomical access is not evidence of clinical effectiveness. Reaching nasal tissue does not prove that light reduces influenza symptoms, changes viral load, or improves recovery.

How intranasal and external light devices should be evaluated

Generic light-device technical documentation review

Device evaluation should begin with the model's intended use and instructions, not with a wavelength number or LED count. For a technically meaningful assessment, documentation should identify:

• Intended use, intended users, anatomical application, and contraindications
• Measured peak wavelength, tolerance, and full width at half maximum
• Irradiance at the actual treatment plane after warm-up
• Whether irradiance is a peak, center-point, minimum, or multi-point average
• Output uniformity across the treatment area
• Continuous or pulsed operation, including duty cycle and time-averaged irradiance
• Thermal stability during the maximum intended session
• Cleaning and disinfection instructions
• Material and biocompatibility information for any mucosal-contact component
• Model-specific eye and skin hazard assessment
• Applicable electrical safety, electromagnetic compatibility, and market documentation

Radiant exposure can be estimated from irradiance and time:

[
\text{Radiant exposure (J/cm²)} = \frac{\text{Irradiance (mW/cm²)} \times \text{Time (seconds)}}{1000}
]

This equation describes incident optical energy. It does not determine a therapeutic dose, account for tissue attenuation, or establish a flu protocol.

Intranasal devices versus external panels

No device format has established clinical effectiveness for influenza.

Intranasal phototherapy has been studied in conditions such as allergic rhinitis. Allergic rhinitis is an allergen-driven inflammatory disorder, not a viral infection, so those findings cannot be relabeled as evidence for influenza, the common cold, COVID-19, or other acute respiratory infections.

External panels illuminate a larger surface area, but surface exposure does not prove that an effective or safe dose reaches the nasal mucosa, trachea, bronchi, lungs, or other internal targets. Wavelength alone cannot establish treatment depth, and muscle aches or fatigue are not evidence-based anatomical targets for flu-directed PBM.

Chest pressure, difficulty breathing, confusion, severe weakness, dehydration, or worsening symptoms should prompt medical assessment rather than experimentation with a light device.

What the evidence actually supports—and where it stops

Researcher comparing different categories of PBM evidence

As of August 2026, the sources reviewed for this article did not identify a randomized controlled trial testing red or near-infrared PBM as a treatment for confirmed human influenza. The available evidence falls into categories that answer different questions:

Accordingly, current evidence does not establish that PBM:

• Prevents influenza infection
• Inactivates influenza virus inside the body
• Reduces influenza viral load
• Relieves flu-related congestion, fever, cough, fatigue, or body aches
• Prevents pneumonia or other complications
• Shortens illness or accelerates recovery
• Provides a validated adjunctive treatment for influenza

Absence of established evidence is not proof that every possible PBM approach is ineffective. It means effectiveness, safety, target, and dose remain unproven and require well-designed human studies before clinical or consumer recommendations can be made.

What safety and compliance documents tell you

Model-specific safety and compliance documents without logos

Safety and compliance documents can be useful, but their scope must be described accurately.

FDA establishment registration and device listing

In the United States, establishment registration and device listing are administrative requirements that help the FDA identify establishments and devices. They do not mean that the FDA has approved, cleared, certified, recognized, or authorized a manufacturer or product. A flu-related indication would need to fit the device's legally supported intended use and applicable regulatory pathway.

CE marking

CE marking indicates that the manufacturer declares conformity with the applicable European Union requirements for the specific product and intended purpose. Electromagnetic-compatibility or electrical-safety documentation does not establish clinical effectiveness. If promotional material assigns a disease-related use, that claim can affect the product's regulatory intended purpose and required evidence.

Optical and medical-electrical safety standards

IEC 62471 provides exposure limits, measurement methods, and a risk-group framework for photobiological hazards from lamps and LED systems. A report must be interpreted with its tested model, operating mode, distance, exposure duration, and risk classification. It does not validate a therapeutic dose or clinical indication.

Depending on the intended use and market, therapeutic non-laser light equipment may also require assessment under medical-electrical standards such as IEC 60601-2-57 and related home-use, usability, risk-management, electrical-safety, and EMC requirements.

ISO 13485 and MDSAP

ISO 13485 and the Medical Device Single Audit Program concern a manufacturer's quality-management system. They can provide evidence that defined processes are documented and audited within the certificate's scope. They do not certify the clinical effectiveness of an individual device or prove that it treats influenza.

All documents should be checked for the exact legal manufacturer, model, configuration, scope, issue and expiry dates, test conditions, and target market. A logo or certificate number without the underlying model-specific documentation is insufficient.

Practical priorities during suspected influenza

Home symptom monitoring with light device switched off

There is no evidence-based nasal, facial, throat, chest, back, or full-body PBM protocol for influenza. Using a light device should not delay testing, medical assessment, vaccination, or antiviral treatment when indicated.

For most people with mild flu, established supportive priorities include rest, adequate fluids, symptom monitoring, and limiting contact with others. People at higher risk of complications—including young children, older adults, pregnant people, immunocompromised people, and those with certain chronic conditions—should contact a healthcare professional early when flu is suspected.

Prescription influenza antivirals provide the greatest benefit when started early, particularly within the first one to two days after symptoms begin, although later treatment may still help people with severe, progressive, or high-risk illness.

Seek urgent medical care for warning signs such as difficulty breathing, persistent chest pain or pressure, confusion, inability to stay awake, severe weakness, dehydration, bluish or pale skin, or symptoms that improve and then return or worsen. A single temperature threshold should not be used as the only decision rule.

Respiratory symptoms can also result from COVID-19, respiratory syncytial virus, the common cold, allergies, or other conditions. Nasal congestion alone does not confirm influenza.

Anyone using a light device for a separate, established intended use while ill should follow the model-specific instructions, cleaning requirements, warnings, and clinician advice. Do not insert a device into the nose or direct a panel at the face, throat, or chest to treat flu unless that exact use is supported by the product's authorized intended use and adequate clinical evidence.

Key takeaways

• PBM has plausible and still-developing cellular mechanisms, but mechanism evidence is not influenza treatment evidence.
• No validated human flu protocol has been established for intranasal red light, external panels, or other PBM formats.
• Allergic-rhinitis studies must not be presented as evidence for a viral respiratory infection.
• Wavelength, irradiance, dose calculations, and safety reports characterize a device; they do not prove clinical effectiveness.
• FDA registration, CE marking, IEC testing, ISO 13485, and MDSAP do not authorize or validate a flu-treatment claim.
• Rest, hydration, symptom monitoring, vaccination, timely antiviral care when indicated, and attention to warning signs remain the evidence-based priorities.

FAQ

Is red light therapy good to use when sick?

Current evidence is not sufficient to recommend red or near-infrared light as a treatment for influenza. Safety also cannot be generalized across devices, because spectrum, output, heat, distance, anatomical use, and warnings differ. Follow the exact model's intended use and instructions, and do not let device use delay medical care.

Does red light therapy help with viruses?

Laboratory PBM research has examined cellular signaling, oxidative stress, and inflammatory pathways, but that is different from demonstrating an antiviral effect in people. There is no reliable human evidence that consumer red or near-infrared PBM reduces influenza viral load, prevents infection, or shortens illness.

Where should red light therapy not be applied?

Follow the model-specific instructions and optical-safety assessment. Do not direct a device at the eyes, insert it into a body opening, apply it over an anatomical site, or use it with a photosensitizing condition or medication unless the product instructions specifically permit that use. Mucosal-contact devices also require validated materials, cleaning instructions, and single-user or reprocessing guidance. Ask a qualified healthcare professional when pregnant, treating a child, managing cancer, using photosensitizing medication, or living with another condition that may change the risk assessment.

Does red light therapy help flu-related congestion?

Clinical evidence has examined some forms of intranasal phototherapy for allergic rhinitis, but allergic rhinitis is not influenza. Current evidence does not establish that nasal red light relieves congestion caused by influenza or other acute viral infections. Congestion can have several causes, so diagnosis-specific care matters.

References

1. World Health Organization. Influenza (seasonal). Updated February 28, 2025.
2. Centers for Disease Control and Prevention. Flu: What to Do If You Get Sick. August 30, 2024.
3. Centers for Disease Control and Prevention. Treating Flu with Antiviral Drugs. Updated June 26, 2026.
4. de Freitas LF, Hamblin MR. Proposed Mechanisms of Photobiomodulation or Low-Level Light Therapy. IEEE Journal of Selected Topics in Quantum Electronics. 2016;22(3):7000417. doi:10.1109/JSTQE.2016.2561201.
5. Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics. 2017;4(3):337–361. doi:10.3934/biophy.2017.3.337.
6. Avci P, Gupta A, Sadasivam M, et al. Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. Seminars in Cutaneous Medicine and Surgery. 2013;32(1):41–52. PMID: 24049929.
7. Neuman I, Finkelstein Y. Narrow-band red light phototherapy in perennial allergic rhinitis and nasal polyposis. Annals of Allergy, Asthma & Immunology. 1997;78(4):399–406. doi:10.1016/S1081-1206(10)63202-4.
8. Nobel Prize Outreach. Niels Ryberg Finsen—Facts.
9. U.S. Food and Drug Administration. Important Reminders about Registration and Listing.
10. International Electrotechnical Commission. IEC 62471:2006—Photobiological safety of lamps and lamp systems.
11. International Electrotechnical Commission. IEC 60601-2-57:2023—Particular requirements for non-laser light source equipment.
12. International Organization for Standardization. ISO 13485—Medical devices quality management systems.
13. European Union. Regulation (EU) 2017/745 on medical devices.